Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sangart raises $50 million

This article was originally published in Scrip

Executive Summary

Sangart has secured $50 million from investors in a series F financing round. The US company will use the proceeds to further the clinical development of its MP4 oxygen therapeutics pipeline. The privately held firm's lead candidate MP4OX combines a unique polyethylene glycol conjugation with human haemoglobin. The candidate is designed with optimal molecular size, viscosity, oxygen affinity and diffusion potential to target tissues with oxygen deprivation in artificial capillaries and animal models. The latest investment brings the total amount invested in the series F round to $100 million.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts